Table 3.

Sensitivity analyses

Sensitivity analysis	Additional CD4+ T-cell gain associated with CCR5 antagonist	No. of arms (no. using CCR5 antagonist )	Total sample size (no. receiving CCR5 antagonist)
Control for baseline CD4+ T-cell count	30 cells/μL (95% CI, 15–45)	Full data set	Full data set
Observed virologic suppression as a  quadratic variable	26 cells/μL (95% CI, 15–38)	Full data set	Full data set
Including only the groups receiving  the investigational agent (ie,  excluding control groups)	27 cells/μL (95% CI, 16–39)	30 (11)	4,337 (1,133)
Include only those groups using  LOCF	27 cells/μL (95% CI, 14–40)	36 (9)	5,063 (1,054)
Include only those groups with <50%  discontinuing prior to week 24	34 cells/μL (95% CI, 23–45)	33 (8)	5,601 (979)
Include only those groups with ≥30%  achieving plasma HIV-1 RNA level  <50 copies/mL at week 24	37 cells/μL (95% CI, 27–47)	22 (7)	3,511 (949)
Maraviroc only (vicriviroc arms  excluded)	27 cells/μL (95% CI, 16–38)	39 (6)	6,347 (964)
Vicriviroc only (maraviroc arms  excluded)	46 cells/μL (95% CI, 9–83)	37 (5)	5,344 (169)

Note: LOCF = last observation carried forward.